Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
Arvinas, Inc. (ARVN) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 7.2 M | -313,800,000 | 644.6 M | 1.3 B | 1.28 B |
| 2022 | 8 M | -75,800,000 | 703.9 M | 1.27 B | 1.24 B |
| 2021 | 25.7 M | -103,300,000 | 799.9 M | 1.58 B | 1.55 B |
| 2020 | 8.44 M | -584,332,970 | 75.11 M | 717.37 M | 703.09 M |
| 2019 | 6.28 M | -4,823,050 | 74.96 M | 301.64 M | 290.88 M |